Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Middle East Respiratory Syndrome (MERS) – Drugs In Development, 2024 report and make more profitable business decisions.
Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Symptoms include fever, cough, and shortness of breath. Other symptoms include nausea, vomiting, and diarrhea. Pneumonia is common, and organs damage can occur to the kidneys or other organs. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.
The Middle East Respiratory Syndrome (MERS) drugs in development market research report provide comprehensive information on the therapeutics under development for Middle East Respiratory Syndrome (MERS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Middle East Respiratory Syndrome (MERS) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Middle East Respiratory Syndrome (MERS) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 71 molecules, with 58 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Middle East Respiratory Syndrome (MERS) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Middle East Respiratory Syndrome (MERS) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Middle East Respiratory Syndrome (MERS) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abcontek IncAchelois BioPharma Inc
AIM ImmunoTech Inc
Aligos Therapeutics Inc
Amide Technologies Inc
Anglo Biopharma Ltd
AstraZeneca Plc
Autoimmune Technologies LLC
Barinthus Biotherapeutics Plc
Beijing Institute of Microbiology & Epidemiology
Beroni Group Ltd
Calder Biosciences Inc
California Institute for Biomedical Research
Chongqing Zhifei Biological Products Co Ltd
Cidara Therapeutics Inc
Cloud Pharmaceuticals Inc
Cocrystal Pharma Inc
ConserV Bioscience Ltd
Dana-Farber Cancer Institute Inc
Dominari Holdings Inc
Everest Medicines Ltd
FUDAN University
Future Medicine Co Ltd
Gamaleya Federal Research Center of Epidemiology and Microbiology
German Center for Infection Research
Global BioLife Inc Ltd
Greffex Inc
Halo Therapeutics Ltd
Immune Biosolutions Inc
Infex Therapeutics Ltd
Intravacc BV
Invivyd Inc
Jordan University of Science and Technology
LegoChem Biosciences Inc
Meletios Therapeutics SAS
Merck & Co Inc
Merck KGaA
Moderna Inc
NanoViricides Inc
Novavax Inc
Oncolys BioPharma Inc
Ostrich Pharma USA Inc
OyaGen Inc
Phelix Therapeutics LLC
Protexase Therapeutics Inc
Pulmotect Inc
Purdue University
Regeneron Pharmaceuticals Inc
ReVacc Biotech
Signia Therapeutics
Sihuan Pharmaceutical Holdings Group Ltd
Spanish National Research Council
Sumagen Co Ltd
Theravectys SA
Thylacine Biotherapeutics Inc
University of Hong Kong
University of Maryland
University of Queensland
University of Strathclyde
University of Texas Medical Branch at Galveston
Valo Therapeutics Oy
VBI Vaccines Inc
Vir Biotechnology Inc
Westlake Pharma Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Middle East Respiratory Syndrome (MERS) reports